Abstract
Most prostate and breast cancers are hormone dependent. The inhibition of steroid 17α-hydroxylase/17,20- lyase (CYP17), which is a crucial enzyme for steroid hormone biosynthesis, is widely used to treat androgen-dependent prostate cancer (PC). CYP17 has dual enzymatic activity: 17alpha-hydroxylase activity (utilizing delta4- C21 steroids as substrates) and the 17,20-lyase activity (using delta5- C21 steroids as substrates). The steroid biosynthetic pathway is directed to either the production of corticosteroids or sex hormones depending on the activity of CYP17. In this review, the current information on the genetics, molecular structure, substrate specificity and inhibitors of CYP17 is analyzed and discussed.
Keywords: Cytochrome P450, CYP17, hormone-dependent cancer, inhibitors of androgen biosynthesis, prostate cancer, steroid hormone biosynthesis, steroid 17α-hydroxylase, 17, 20-lyase.
Anti-Cancer Agents in Medicinal Chemistry
Title:Genetics, Structure, Function, Mode of Actions and Role in Cancer Development of CYP17
Volume: 14 Issue: 1
Author(s): Tatyana. A Sushko, Andrei A. Gilep and Sergey A. Usanov
Affiliation:
Keywords: Cytochrome P450, CYP17, hormone-dependent cancer, inhibitors of androgen biosynthesis, prostate cancer, steroid hormone biosynthesis, steroid 17α-hydroxylase, 17, 20-lyase.
Abstract: Most prostate and breast cancers are hormone dependent. The inhibition of steroid 17α-hydroxylase/17,20- lyase (CYP17), which is a crucial enzyme for steroid hormone biosynthesis, is widely used to treat androgen-dependent prostate cancer (PC). CYP17 has dual enzymatic activity: 17alpha-hydroxylase activity (utilizing delta4- C21 steroids as substrates) and the 17,20-lyase activity (using delta5- C21 steroids as substrates). The steroid biosynthetic pathway is directed to either the production of corticosteroids or sex hormones depending on the activity of CYP17. In this review, the current information on the genetics, molecular structure, substrate specificity and inhibitors of CYP17 is analyzed and discussed.
Export Options
About this article
Cite this article as:
Sushko A Tatyana., Gilep A. Andrei and Usanov A. Sergey, Genetics, Structure, Function, Mode of Actions and Role in Cancer Development of CYP17, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/187152061131300330
DOI https://dx.doi.org/10.2174/187152061131300330 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Neuroinflammation on ABC Transporters: Possible Contribution to Refractory Epilepsy
CNS & Neurological Disorders - Drug Targets Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Recent Advances on Liquid Chromatographic and Mass Spectrometric Analysis of Selective Estrogen Receptor Modulators (SERMs) in Biological Fluids
Current Chromatography Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Current Medicinal Chemistry The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Propagation on Molecular Interaction Networks: Prediction of Effective Drug Combinations and Biomarkers in Cancer Treatment
Current Pharmaceutical Design A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas
Current Signal Transduction Therapy Application of Decoy Oligodeoxynucleotides-Based Approach to Renal Diseases
Current Drug Targets A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Procarbazine – A Traditional Drug in the Treatment of Malignant Gliomas
Current Medicinal Chemistry Endogenous Enzyme-responsive Nanoplatforms for Anti-tumor Therapy
Current Drug Targets Polyphenols and Cardiovascular Disease: A Critical Summary of the Evidence
Mini-Reviews in Medicinal Chemistry C7-Substituted Estranes and Related Steroids
Mini-Reviews in Organic Chemistry Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry